12 Best Stocks to Invest in for a Stock Market Game
We all have heard the phrase ‘value isn’t always visible at first glance’ at least once in our lifetime and this isn’t something to overlook, particularly when you are playing the stock game.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 3,823,527 | $7,264,701 | +3% | 0.01% |
| 2. | Citadel Investment Group Ken Griffin | 1,382,146 | $2,626,077 | 0% | |
| 3. | Balyasny Asset Management Dmitry Balyasny | 274,452 | $521,459 | 0% | |
| 4. | Exome Asset Management Samuel Isaly | 205,956 | $391,316 | 0.29% | |
| 5. | Millennium Management Israel Englander | 169,647 | $322,329 | +738% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.43 | 5,800 | 29,731 | 2019-11-20 | Filing | ||
| $3.52 | 15,000 | 28,700 | 2019-11-20 | Filing | ||
| $3.58 | 27,000 | 37,000 | 2019-11-20 | Filing | ||
| $3.44 | 50,000 | 887,732 | 2019-11-20 | Filing | ||
| $3.41 | 50,000 | 63,700 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.83 | 46,409 | 2,557,921 | 2025-03-03 | Filing | ||
| $1.83 | 7,144 | 809,090 | 2025-03-03 | Filing | ||
| $2.10 | 97,982 | 2,604,330 | 2025-02-03 | Filing | ||
| $2.10 | 46,268 | 2,702,312 | 2025-02-03 | Filing | ||
| $2.10 | 27,236 | 816,234 | 2025-02-03 | Filing |
Institutional Investors' Holdings
News See All
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call Transcript
Operator: Good day, and welcome to Akebia's Fourth Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akebia Therapeutics' Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2023 Earnings Call Transcript
Operator: Good day and welcome to Akebia's Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Akebia's First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript
Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebia's Fourth Quarter 2022 Financial Results Conference Call.
5 Underperforming Stocks Targeted By Short Sellers
In this article we discuss top 5 underperforming stocks targeted by short sellers.
Is AKBA A Good Stock To Buy Now?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...